Therapeutic Asset Ratings

396 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE Steroid Synthesis Inhibitors	Eli Lilly and Company	P3	B (60)
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE Urinary System Neoplasm	Eli Lilly and Company	P3	B (60)
DEXAMETHASONE Central Nervous System Disorder	Eli Lilly and Company	P3	B (60)
DEXAMETHASONE Nervous System Disorder	Eli Lilly and Company	P3	B (60)
DEXAMETHASONE Neurocognitive Disorders	Eli Lilly and Company	P3	B (60)
DEXAMETHASONE Neurodegenerative Disease	Eli Lilly and Company	P3	B (60)
Donanemab Mental Disorder	Eli Lilly and Company	P3	B (60)
Donanemab Mild Cognitive Impairment (MCI)	Eli Lilly and Company	P3	B (60)
Donanemab Nervous System Disorder	Eli Lilly and Company	P3	B (60)
Donanemab Neurocognitive Disorders	Eli Lilly and Company	P3	B (60)
Donanemab Neurodegenerative Disease	Eli Lilly and Company	P3	B (60)
Donanemab Senile Plaque Formation	Eli Lilly and Company	P3	B (60)
Donanemab Tauopathy	Eli Lilly and Company	P3	B (60)
Eloralintide Osteoarthritis	Eli Lilly and Company	P3	B (60)
Eloralintide Obstructive Sleep Apnea Syndrome	Eli Lilly and Company	P3	B (60)
Hycamtin Fallopian Tube Neoplasm	Eli Lilly and Company	P3	B (60)
Imlunestrant Breast Neoplasm	Eli Lilly and Company	P3	B (60)
LEUPROLIDE Distant Metastasis	Eli Lilly and Company	P3	B (60)
Mirikizumab Crohn Disease	Eli Lilly and Company	P3	B (60)
Mirikizumab Obesity Disorder	Eli Lilly and Company	P3	B (60)
Mirikizumab Ulcerative Colitis	Eli Lilly and Company	P3	B (60)
Mirvetuximab Soravtansine Fallopian Tube Neoplasm	Eli Lilly and Company	P3	B (60)
Mirvetuximab Soravtansine Peritoneal Neoplasm	Eli Lilly and Company	P3	B (60)
Orforglipron Atherosclerotic Cardiovascular Disease	Eli Lilly and Company	P3	B (60)
Orforglipron Cardiovascular Disorder	Eli Lilly and Company	P3	B (60)

Showing 101 to 125 of 396 assets

PreviousPage 5 of 16Next